文献速递复苏、休克与脓毒症创伤与烧伤

猪出血与缺血再灌注损伤模型中血管内可变主动脉控制(EVAC)与复苏性血管内球囊阻断主动脉(REBOA)的比较

Endovascular variable aortic control (EVAC) versus resuscitative endovascular balloon occlusion of the aorta (REBOA) in a swine model of hemorrhage and ischemia reperfusion injury.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论在猪控制性出血模型中,短时EVAC较REBOA近端血压更接近生理、复苏期晶体液和血管活性药需求更少、乳酸更低、再灌注主动脉高灌注更轻;作者认为EVAC是院内不可压迫性出血性休克可行策略,但需生存研究验证。

本研究在12头约克郡杂交猪中建立控制性25%出血模型,随机接受45分钟EVAC或REBOA干预,随后全血复苏及6小时重症监护。干预期间EVAC近端血压增幅更接近生理(101 vs 129 mmHg,P=0.04)。重症监护期间EVAC所需晶体液不足REBOA一半(3450 mL vs 7400 mL,P<0.01),血管活性药用量更少(21.5 vs 50.5 ng/kg,P=0.05),乳酸峰值和终值更低,再灌注后主动脉血流更接近基线(36 vs 51 mL/kg/min,P=0.01)。作者认为短时EVAC在血流动力学和缺血损伤方面优于REBOA,是院内不可压迫性出血性休克可行策略,但需生存研究确定早期差异是否持续。

要点

  • 猪控制性25%出血模型、45分钟干预:EVAC组近端血压增幅101 mmHg vs REBOA组129 mmHg(P=0.04),更接近生理。
  • 重症监护期EVAC组晶体液3450 mL vs REBOA组7400 mL(P<0.01),不足后者一半。
  • EVAC组血管活性药21.5 ng/kg vs REBOA组50.5 ng/kg(P=0.05),用量更少。
  • EVAC组乳酸峰值和终值更低,再灌注后主动脉血流36 vs 51 mL/kg/min(P=0.01),更接近基线。
  • 作者认为短时EVAC是院内不可压迫性出血性休克可行策略,但需生存研究验证早期差异是否持续。

适用人群与场景

  • 猪控制性25%出血模型,12头约克郡杂交猪,干预时长45分钟,后续全血复苏及6小时重症监护。

研究设计与关键结果

  • 研究类型:猪控制性出血与缺血再灌注损伤模型,样本量12头约克郡杂交猪,比较自动EVAC与REBOA,干预45分钟,后续全血复苏及6小时重症监护。
  • 基线参数无差异。
  • 干预期间近端血压增幅:EVAC组101 mmHg vs REBOA组129 mmHg(95%CI 105-151 mmHg,P=0.04),EVAC更接近生理。
  • 重症监护期间晶体液用量:EVAC组3450 mL(95%CI 1215-5684 mL)vs REBOA组7400 mL(95%CI 6148-8642 mL),P<0.01。
  • 重症监护期间血管活性药用量:EVAC组21.5 ng/kg(95%CI 7.5-35.5 ng/kg)vs REBOA组50.5 ng/kg(95%CI 40.5-60.5 ng/kg),P=0.05。
  • EVAC组乳酸峰值和终值更低。
  • 再灌注后主动脉血流:EVAC组36 mL/kg/min(95%CI 30-44 mL/kg/min)vs REBOA组51 mL/kg/min(95%CI 41-61 mL/kg/min),P=0.01,EVAC组主动脉高灌注更轻、更接近基线。

证据类型、等级与局限

  • 证据类型:动物实验(猪控制性出血模型)。
  • 局限:作者指出需生存研究以确定这些早期差异是否随时间持续。

对床旁实践的改变

  • 作者认为,在短时治疗条件下,EVAC在血流动力学和缺血损伤方面优于REBOA,是院内不可压迫性出血性休克可行策略。
  • 作者指出需生存研究确定早期差异是否持续。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is effective at limiting hemorrhage from noncompressible sources and restoring but causes progressive distal ischemia, supraphysiologic pressures, and increased cardiac afterload. Endovascular variable aortic control (EVAC) addresses these limitations, while still controlling hemorrhage. Previous work demonstrated improved outcomes following a 90-minute intervention period in an uncontrolled hemorrhage model. The present study compares automated EVAC to REBOA over an occlusion period reflective of contemporary REBOA usage.

METHODS: Following instrumentation, 12 Yorkshire-cross swine underwent controlled 25% hemorrhage, a 45-minute intervention period of EVAC or REBOA, and subsequent resuscitation with whole blood and critical care for the remainder of a 6-hour experiment. Hemodynamics were acquired continuously, and laboratory parameters were assessed at routine intervals. Tissue was collected for histopathologic analysis.

RESULTS: No differences were seen in baseline parameters. During intervention, EVAC resulted in more physiologic proximal pressure augmentation compared with REBOA (101 vs. 129 mm Hg; 95% confidence interval [CI], 105-151 mm Hg; p = 0.04). During critical care, EVAC animals required less than half the amount of crystalloid (3,450 mL; 95% CI, 1,215-5,684 mL] vs. 7,400 mL [95% CI, 6,148-8,642 mL]; p < 0.01) and vasopressors (21.5 ng/kg [95% CI, 7.5-35.5 ng/kg] vs. 50.5 ng/kg [95% CI, 40.5-60.5 ng/kg]; p = 0.05) when compared with REBOA animals. Endovascular variable aortic control resulted in lower peak and final lactate levels. Endovascular variable aortic control animals had less aortic hyperemia from reperfusion with aortic flow rates closer to baseline (36 mL/kg per minute [95% CI, 30-44 mL/kg per minute] vs. 51 mL/kg per minute [95% CI, 41-61 mL/kg per minute]; p = 0.01).

CONCLUSIONS: For short durations of therapy, EVAC produces superior hemodynamics and less ischemic insult than REBOA in this porcine-controlled hemorrhage model, with improved outcomes during critical care. This study suggests EVAC is a viable strategy for in-hospital management of patients with hemorrhagic shock from noncompressible sources. Survival studies are needed to determine if these early differences persist over time.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Williams TK, Tibbits EM, Hoareau GL, et al. Endovascular variable aortic control (EVAC) versus resuscitative endovascular balloon occlusion of the aorta (REBOA) in a swine model of hemorrhage and ischemia reperfusion injury. J Trauma Acute Care Surg. 2018. PMID: 30142105. doi:10.1097/TA.0000000000002008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。